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Accepted 20 July 2011; Published online 12 October 2011In his commentary, Taves [1] has expressed the view that
minimization should be the uniformly adopted way of as-
signing patients to treatments in comparative clinical trials,
with a particular emphasis on the advantages of rank min-
imization. In advocating it as the ‘‘platinum standard,’’
Taves proposes that the question mark in the title of Trea-
sure and MacRae’s [2] editorial is to be removed.
Minimization has been usefully adopted in a variety of
trials. It places overriding importance on the achievement
of marginal balance with respect to patient characteristics
in the treatment groups to be compared. One particular ben-
efit of this is that of being able to demonstrate to skeptics
that the treatment groups are otherwise comparable and
that, therefore, any difference must be because of different
assigned treatments. A second is that, in many circum-
stances, balance across important prognostic factors will
provide an efficiency gain in the estimation of treatment ef-
fects and therefore provide a more powerful study.
Interestingly, there is a parallel with the arguments for
randomization in experimental design. As outlined by
Cox [3], there are two positive advantages to randomiza-
tion. These are the following:
1. to ensure that the observed treatment effect provides
a "good" (unbiased) estimate of the true treatment ef-
fect (i.e., the trial answers the right question),
2. to provide a means to measure the random error of the
estimated treatment effect (i.e., to provide a basis for
inference).
The second advantage facilitates certain types of statis-
tical inference but is essentially a mathematical feature of
randomization and so does not carry much weight on clin-
ical or ethical grounds. From the medical perspective, the
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doi: 10.1016/j.jclinepi.2011.07.005Taves argues that minimization also achieves the first ad-
vantage of randomization, which is essentially that of unbi-
ased treatment allocation. The possibility of selection bias
with minimization, by its nature, remains a possibility so
the argument can never be ‘‘open and shut.’’ If there is
any suspicion that the inclusion or exclusion of patients
in the trial was amenable to manipulation in the light of
knowledge of the likely next allocation, the fundamental
principle, that there is no bias in the allocation, is jeopar-
dized. There is no doubt that conscious or unconscious bias
is a major problem in research, and it is na€ıve to think oth-
erwise. Individual medical and nursing staff may exercise
their biases for what they see as the highest of motives in
caring for patients. That is perhaps why many experienced
designers of trials prefer to introduce a degree of random-
ness into minimization by choosing the assignment that is
most helpful to marginal balance with high probability
but not with certainty. Perhaps this, along with the first ben-
efit of minimization mentioned above, is sometimes cos-
metic but a trial is successful only if it is broadly
convincing so this is not unimportant. Thus, we would also
advocate some degree of randomization when minimization
is adopted.
A very useful reference for a discussion of how to deal
with prognostic factors in clinical trials is Rosenberger
and Sverdlov [4]. This article makes it clear that there are
not always simple answers to how these should be incorpo-
rated into the design of trials. For example, they demon-
strate that balancing on covariates may not always lead to
the most efficient designs when nonlinear models are to
be used. Careful technical investigations are required to ad-
dress such matters, and there is a growing literature of this
type related to minimization. Similarly, technical investiga-
tions of the loss in efficiency through the use of categorized
continuous variables in analysis have been undertaken [5],
but the extent to which these carry over to design has, to our
knowledge, not been investigated. Thus the quantitative
advantage of rank minimization compared with that based
on categories is yet to be fully determined.
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Minimization is infrequently used. Discussion of
this approach to unbiased allocation is to bewelcomed,
and we illustrate its application in the evaluation of
interventions while adding some cautionary notes.
Rosenberger and Sverdlov [4] highlight that many views
of minimization are expressed in ‘‘opinion pieces’’ and that
‘‘the nonspecificity of language in these opinion pieces is
becoming troubling.’’ Taves’ commentary [1] is quite ap-
propriately an opinion piece and limited in its technical ar-
guments but, nevertheless, we suggest that it is perhaps too
early to assign ‘‘platinum status’’ to rank minimization on
the basis of it and previous articles on the topic. Similarly,
the advocacy of a two-stage analysis which gives separation
between the primary trial analysis and the design in terms
of the number of prognostic factors for which adjustment
is made warrants further investigation before adoption,
minimally with respect to some quantification of the in-
equalities associated with significance levels. In our ‘‘opin-
ion,’’ we feel that balancing on an excessive number of
factors is seldom necessary in practice.
We now consider the specific context of surgical trials. It
is 15 years since The Lancet published an inflammatory ed-
itorial likening surgical research to ‘‘Comic Opera’’ [6].
The grounds for criticism were Horton’s finding a plethora
of case series and a dearth of controlled trials in recent sur-
gical journals. It is true that much of surgical practice is
based not on evidence from clinical trials but on the re-
peated fixing of a problem in a rather obviously mechanis-
tic and reproducible way. Where the cause and effect
relationship between surgical endeavor and clinical out-
come is less clear, a controlled trial is needed. Any means
that leads to randomized controlled trials in surgery being
more often done, and that might help to give clinically use-
ful answers with relatively small numbers, is welcome. The
truism ‘‘some unbiased evidence is clearly better than
none’’ [7] makes it worth striving to ensure that allocation
bias is seen to be excluded. Thus, the advantage of minimi-
zation in ensuring balance is very attractive.
This is particularly true in cancer surgery where it has be-
come impossible todiscern ‘‘signal fromnoise’’ [8] for awhole
list of reasons. There is wide variation in cancer stage at pre-
sentation and in its rate of progression. The better cases are
selected by experienced and highly intelligent clinicians for
their more demanding treatments, and they may well know
how to pickwinners. It is then impossible to separate selection
for the treatment from the effect of the treatment: the fact that
surgery was performed may be associated with a better out-
come than seen in patients not selected, rather than that the
act of surgery gave the benefit. The degree of selection cannot
be estimated and may be only a few percent of possible candi-
dates. In follow-up studies, the size of the denominator israrely stated and is often unknown or unknowable. It also is
in the nature of follow-up studies that the patients to be
included are identified by having completed treatment rather
than on intention to treat. There is a current mind-set of throw-
ing everything at the cancer: multiple therapies are used in
sequence or in combination. The completion of treatment
takes time and involves sequential selection, thus further asso-
ciating treatment with survival while not necessarily influenc-
ing it. Contemporary notions of ‘‘personalised’’ therapy
further confuse the picture: treating by protocol is deliberately
set aside as the clinician applies successive treatments by
‘‘clinical judgement.’’ There are thus many ways in which
there is an illusion of benefit greater than the reality [9]. Taking
asbestos-related cancer as an example, it is generally accepted
by surgeons and pathologists that, at a mechanistic level, even
the most radical surgery consistently fails to clear pleural me-
sothelioma and so fails in the primary objective of all cancer
surgery [10]. Yet a survey of 802 thoracic surgeons revealed
that 50% of American surgeons believed that mesothelioma
could be cured by surgery alone [11,12].
It was against such a background that the Mesothelioma
and Radical Surgery (MARS) trial was performed. MARS,
the only surgical study of mesothelioma ever to include
a randomized control group, found that those who had the
chemotherapy without the surgery fared better in terms of
both survival and quality of life, but only if adjustment
was made for gender, histological subtype, stage, and age
at randomization. Unadjusted survival was not significantly
different (P5 0.08) [13]. MARS was of necessity a small
trial with 50 patients and might have been seen as a prime
candidate for minimization. Although it must be remem-
bered that, in some cases, adjusted and unadjusted analyses
simply answer different questions, in this case, the differ-
ence between these two analyses might yet undermine the
impact of the trial. We cannot know what would have
happened if minimization had been used but preventing
a problem is usually better than fixing it later.
Minimization offers the opportunity to ensure balance
between the groups. Unlike laboratory scientists who can
study rats of the same sex, age, and of similar weights, clin-
ical researchers’ subjects come in all shapes and sizes, with
a range of patient-related factors that may have a larger
effect on the outcome of interest than the likely difference
between the two interventions. For example, in the choice
between heart valves the variations in outcome attributable
to the patients’ age and left ventricular function were likely
to be greater than the differences attributable to the subtle-
ties of valve design [14]. Based on follow-up studies from
different eras, and with differing case mix, there was a per-
ception that one valve performed better than another. When
these patient-related factors were balanced by minimiza-
tion, and a controlled trial was performed, the believed dif-
ference in outcome between the valves disappeared and
tended to reverse [15].
In our own present surgical study of pulmonary metasta-
sectomy in colorectal cancer (PulMiCC) [16,17], we know
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repeatedly in multivariable analysis to influence outcome,
including the number of metastases, the time course of their
appearance, the level of carcinoma embryonic antigen, and
the patient’s age and sex, and we will include them in the
allocation by minimization, which combines an element
of randomization. It is a multicenter study, and the compu-
tation is made at the trial center, and no participants have
access to the data or details of computation.
The need for controlled studies now is even greater than
back in the day of writing ‘‘Comic Opera,’’ but the 50%
chance by random allocation to not receive an intervention
is perceived by many clinicians as an insurmountable obsta-
cle to recruiting patients into studies. It is usually said that
patients will not accept ‘‘random’’ allocation of treatment,
but this was not the experience in MARS [13]. We believe
more of a problem is clinicians’ or surgeons’ reluctance to
accept uncertainty and to make an explicit declaration to
the patient that there is doubt. In PulMiCC, we recognize
that recruitment of patients is likely to be slow and arduous,
and eventual numbers are likely to be modest. Any imbal-
ance in the groups will allow those who do not like the re-
sult to explain it away, and all our efforts will be wasted. A
group of patients allocated in an unbiased way into two
groups willing to be cared for within a trial protocol is
a scarce and precious resource.
Minimization is a creative contribution to the design of
clinical trials and can offer some significant potential advan-
tages. At the same time, there are many factors that can influ-
ence the design of trials, and no design can anticipate all the
‘‘surprises’’ that the conduct of a trial may reveal. Given this,
and the lack of definitive technical information concerning
its use, it is pragmatic to make use of minimization when
it will be particularly helpful but to refrain, for now, from
assigning it platinum status.Acknowledgment
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